Release of Plasminogen Activator from Isolated Perfused Dog Heart

Fujio Matsubara; Katsuo Sueishi; Yutaka Ishii; Kenzo Tanaka

doi:10.1055/s-0038-1661251

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1985; 53(01): 126-129
DOI: 10.1055/s-0038-1661251

Original Article

Schattauer GmbH Stuttgart

Release of Plasminogen Activator from Isolated Perfused Dog Heart

Fujio Matsubara

The Department of Pathology, Faculty of Medicine, Kyushu University, Maidashi, Fukuoka, Japan

,

Katsuo Sueishi

The Department of Pathology, Faculty of Medicine, Kyushu University, Maidashi, Fukuoka, Japan

,

Yutaka Ishii

The Department of Pathology, Faculty of Medicine, Kyushu University, Maidashi, Fukuoka, Japan

,

Kenzo Tanaka

The Department of Pathology, Faculty of Medicine, Kyushu University, Maidashi, Fukuoka, Japan

› Author Affiliations

Abstract

PDF Download

Summary

The release and the local activity of plasminogen activator (PA) were studied in isolated perfused dog hearts, without or with intimal injury induced by means of a balloon catheter inserted into the left anterior descending coronary artery (LAD). Thrombin but not DFP-thrombin induced a dose-dependent PA release in doses of 8 to 32 units. ADP 20 or 200 μmol but not ergonovine 20 or 200 μg induced a weak PA release. The local PA activity was much lower in the LAD at 1 or 4 weeks after this injury than in the intact LAD. However, the release of PA from the hearts after intimal injury was similar to findings in the intact hearts.

We conclude from this study that thrombin plays an important role in regulating the coagulation-fibrinolysis system in endothelial cells and that changes in the properties of the endothelial cells may lead to initiation and enhancement of atherosclerosis.

Key words

Plasminogen activators - Coronary perfusion - Thrombin - Intimal injury - Arteriosclerosis

PDF (583 kb)

References

References
1 Todd AS. The histological localisation of fibrinolysin activator. J Pathol Bacteriol 1959; 78: 281-283
2 Holemans R, Johnston JG, Reddick RL. Release of plasminogen activator by the isolated perfused dog kidney. Nature 1965; 208: 291-292
3 Kwaan HC. Physiologic and pharmacologic implications of fibrinolysis. Artery 1979; 5: 285-290
4 Onoyama K, Tanaka K. Fibrinolytic activity of the arterial wall. Thrombos Diathes Haemorrh 1969; 21: 1-11
5 Chapman I. The cause-effect relationship between recent coronary artery occlusion and acute myocardial infarction. Am Heart J 1974; 87: 267-271
6 Wiener L, Kasparian H, Duca PR, Walinsky P, Gottlieb RS, Hanckel F, Brest AN. Spectrum of coronary arterial spasm. Clinical, angiographic and myocardial metabolic experience in 29 cases Am J Cardiol 1976; 38: 945-955
7 Lundblad RL, Kingdon HS, Mann KG. Thrombin. Methods Enzymol 1976; 45: 156-176
8 Thompson AR. High affinity binding of human and bovine thrombins to p-chlorobenzylamido-£-aminocaproyl agarose. Biochim Biophys Acta 1976; 422: 200-209
9 Deutsch DG, Mertz ET. Plasminogen: Purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
10 Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 1952; 40: 346-351
11 Kwaan HC, Astrup T. Localization of fibrinolytic activity in the eye. Arch Pathol 1963; 76: 595-601
12 Baumgartner H-R. Eine neue Methode zur Erzeugung von Thromben durch gezielte Überdehnung der Gefäßwand. Z Ges Exp Med 1963; 137: 227-247
13 Klöcking H-P, Bock G, Drawert J, Hinsenbrock K-P, Kaiser B, Sedlarik U. Über die Freisetzung von Plasminogenaktivatoren. Folia Haematol (Leipz) 1976; 103: 404-424
14 Kitaguchi H, Hijikata A, Hirata M. Effect of thrombin on plasminogen activator release from isolated perfused dog leg. Thromb Res 1979; 16: 407-420
15 Hijikata A, Hirata M, Kitaguchi H. Effect of proteases on plasminogen activator release from isolated perfused dog leg. Thromb Res 1980; 20: 521-531
16 Nakajima K. Pharmacological observations of plasminogen activator release caused by vasoactive agents in isolated perfused pig ears. Thromb Res 1983; 29: 163-174
17 Emeis JJ. Perfused rat hindlegs. A model to study plasminogen activator release Thromb Res 1983; 30: 195-203
18 Galdal KS, Evensen SA. Effects of divalent cations and various vasoactive and haemostatically active agents on the integrity of monolayers of cultured human endothelial cells. Thromb Res 1981; 21: 273-284
19 Klöcking H-P, Jablonowski Ch, Markwardt F. Studies on the release of plasminogen activator from the isolated rat lung by serine protein-ases. Thromb Res 1981; 23: 375-379
20 Awbrey BJ, Hoak JC, Owen WG. Binding of human thrombin to cultured human endothelial cells. J Biol Chem 1979; 254: 4092-4095
21 Hatton MW C, Berry LR, Regoeczi E. Inhibition of thrombin by antithrombin III in the presence of certain glycosaminoglycans found in the mammalian aorta. Thromb Res 1978; 13: 655-670
22 Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982; 257: 7944-7947
23 Bergmann JS, Carney DH. Receptor-bound thrombin is not internalized through coated pits in mouse embryo cells. J Cell Biochem 1982; 20: 247-258
24 Loskutoff DJ, Edgington TS. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sri USA 1977; 74: 3903-3907
25 Ljungnér H, Bergqvist D. Comparison of plasminogen activator activity in human arteries and veins. Thromb Res 1983; 31: 779-786
26 Swedenborg J, Dryjski M, Olsson P. Inactivation of thrombin by the aortic endothelium. Thromb Haemostas 1983; 50: 635-638
27 Busch C, Cancilla PA, DeBault LE, Goldsmith JC, Owen WG. Use of endothelium cultured on microcarriers as a model for the microcirculation. Lab Invest 1982; 47: 498-504
28 Ishida T, Tanaka K. Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture. Atherosclerosis 1982; 44: 161-174
29 Aoki N. Natural inhibitors of fibrinolysis. Prog Cardiovasc Dis 1979; 21: 267-286
30 Noordhoek Hegt V. Inhibition of fibrinolysis by the human vascular wall related to the presence of smooth muscle cells. Haemostasis 1974; 3: 118-128
31 Okamura T, Nanno S, Sueishi K, Tanaka K. Inhibitor of plasminogen activator in human arterial wall. I. Histochemical study. Acta Pathol Jpn 1984; 34: 743-747
32 Dosne AM, Dupuy E, Bodevin E. Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb Res 1978; 12: 377-387
33 Björkerud S, Bondjers G. Arterial repair and atherosclerosis after mechanical injury. Part 1. Permeability and light microscopic characteristics of endothelium in non-atherosclerotic and atherosclerotic lesions. Atherosclerosis 1971; 13: 355-363
34 Highsmith RF. Isolation and properties of a plasminogen activator derived from canine vascular tissue. J Biol Chem 1981; 256: 6788-6795
35 Binder BR, Spragg J, Austin KF. Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates. J Biol Chem 1979; 254: 1998-2003
36 Laug WE. Secretion of plasminogen activators by cultured bovine endothelial cells: Partial purification, characterization and evidence for multiple forms. Thromb Haemostas 1981; 45: 219-224
37 Levin EG, Loskutoff DJ. Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol 1982; 94: 631-636